-
Pozen Inc. v. Par Pharmaceutical, Inc. DC CAFC
- 6:08-cv-00437
- E.D. Tex.
- Judge: Leonard Davis
- Filed: 11/14/2008
- Closed: 08/05/2011
- Latest Docket Entry: 04/07/2017
- PACER
- Docket updated daily
1
Plaintiff
3
Defendants
1
Accused
Product
3
Patents-in-Suit
995
Days in
Litigation
-
Pozen Inc. v. Par Pharmaceutical, Inc. DC CAFC
- 6:08-cv-00437
- E.D. Tex.
- Judge: Leonard Davis
- Filed: 11/14/2008
- Closed: 08/05/2011
- Latest Docket Entry: 04/07/2017
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
The tablet of claim 1, wherein said naproxen is in the form of naproxen sodium at between 200 and 600 mg.
|
Enforceable and Valid
Entry 416 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 15 |
The improvement, method, or composition of claims 1, 2, 3, 4, 5, 6, 7, or 8, wherein said 5-HT agonist is sumatriptan, said LA-NSAID is naproxen and the unit dosage form is an oral unit dosage form comprising sumatriptan in an amount greater than
view more
|
Enforceable and Valid
Entry 416 |
-
Infringement
Alphapharm Party Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 500 mg naproxen sodiumGeneric TreximetTablet for oral administration containing 85 mg sumatriptan | US 6,060,499 A |
15
|
Infringement
Entry 417Entry 416 |
| 500 mg naproxen sodiumGeneric TreximetTablet for oral administration containing 85 mg sumatriptan | US 6,586,458 B1 | All Asserted Claims |
Infringement
Entry 417Entry 416 |
| ANDA No. 90-872Generic Treximet | US 7,332,183 B2 |
2
|
Infringement
Entry 416Entry 312 |
Dr. Reddy's Lab., Inc.
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 500 mg naproxen sodiumGeneric TreximetTablet for oral administration containing 85 mg sumatriptan | US 6,060,499 A |
15
|
Infringement
Entry 417Entry 416 |
| 500 mg naproxen sodiumGeneric TreximetTablet for oral administration containing 85 mg sumatriptan | US 6,586,458 B1 | All Asserted Claims |
Infringement
Entry 417Entry 416 |
| 500 mg naproxen sodiumGeneric TreximetTablet for oral administration containing 85 mg sumatriptan | US 7,332,183 B2 |
2
|
Infringement
Entry 417Entry 416 |
Par Pharmaceutical, Inc.
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 500 mg naproxen sodiumGeneric TreximetTablet for oral administration containing 85 mg sumatriptan | US 6,060,499 A |
15
|
Infringement
Entry 417Entry 416 |
| 500 mg naproxen sodiumGeneric TreximetTablet for oral administration containing 85 mg sumatriptan | US 6,586,458 B1 | All Asserted Claims |
Infringement
Entry 417Entry 416 |
| 500 mg naproxen sodiumGeneric TreximetTablet for oral administration containing 85 mg sumatriptan | US 7,332,183 B2 |
2
|
Infringement
Entry 417Entry 416 |
